Medicine
Terazosin 2 mg capsule
Terazosin 2 mg capsule is a generic prescription medicine for oral use, made by 17 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Terazosin
- Brand
- Sold under the generic name
- Strength
- 2 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 100 capsules, 1000 capsules, 500 capsules and 55 more
- Manufacturers
- Jubilant Cadista PharmaceuticalsIndiaAjanta PharmaIndiaAvet PharmaceuticalsIndiaAphena Pharma Solutions - TennesseeAmerisynAmici PharmaApnar PharmaBionpharmaChartwell RX17 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G04CA03 Terazosin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 December 2004
- Identifiers
- RxCUI 260376, 313215, 313217 +1DailyMed set ID bed99c2a-4266-4a2c-bb0f-7643fdafff78, 9e7b27a6-cc09-407e-e053-2a95a90a17b3, 5680d373-0f61-baf8-e063-6394a90ab8a6 +21NDC 27241-289, 50268-765, 87564-007 +21Application ANDA219482, ANDA075317, ANDA074823 +2
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
A sample of 40 packs from 17 labelers. The register lists 58 packs for this generic presentation, and we confirm the exact pack on the quote.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 capsule in 1 bottle | 27241-289-01 | Ajanta PharmaIndia | 12 May 2025 |
| 1000 capsule in 1 bottle | 27241-289-10 | Ajanta PharmaIndia | 12 May 2025 |
| 100 capsule in 1 bottle | 23155-736-01 | Avet PharmaceuticalsIndia | 30 April 2021 |
| 1000 capsule in 1 bottle | 23155-736-10 | Avet PharmaceuticalsIndia | 30 April 2021 |
| 100 capsule in 1 bottle | 59746-384-06 | Jubilant Cadista PharmaceuticalsIndia | 20 December 2004 |
| 500 capsule in 1 bottle | 59746-384-09 | Jubilant Cadista PharmaceuticalsIndia | 20 December 2004 |
| 1000 capsule in 1 bottle | 59746-384-10 | Jubilant Cadista PharmaceuticalsIndia | 20 December 2004 |
| 90 capsule in 1 bottle | 59746-384-90 | Jubilant Cadista PharmaceuticalsIndia | 20 December 2004 |
| 1000 capsule in 1 bottle | 87564-007-01 | Amerisyn | 1 July 2026 |
| 100 capsule in 1 bottle | 87564-007-10 | Amerisyn | 1 July 2026 |
| 1000 capsule in 1 bottle | 87564-082-01 | Amerisyn | 7 August 2026 |
| 100 capsule in 1 bottle | 87564-082-10 | Amerisyn | 7 August 2026 |
| 100 capsule in 1 bottle | 69292-202-01 | Amici Pharma | 20 May 2026 |
| 1000 capsule in 1 bottle | 69292-202-10 | Amici Pharma | 20 May 2026 |
| 100 capsule in 1 bottle | 24689-002-01 | Apnar Pharma | 7 August 2026 |
| 1000 capsule in 1 bottle | 24689-002-10 | Apnar Pharma | 7 August 2026 |
| 100 capsule in 1 bottle | 69452-331-20 | Bionpharma | 11 March 2024 |
| 1000 capsule in 1 bottle | 69452-331-32 | Bionpharma | 20 December 2024 |
| 90 capsule in 1 bottle | 62135-459-90 | Chartwell RX | 1 February 2023 |
| 30 capsule in 1 bottle | 71610-510-30 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 60 capsule in 1 bottle | 71610-510-53 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 90 capsule in 1 bottle | 71610-510-60 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 120 capsule in 1 bottle | 71610-510-70 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 180 capsule in 1 bottle | 71610-510-80 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 270 capsule in 1 bottle | 71610-510-92 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 360 capsule in 1 bottle | 71610-510-94 | Aphena Pharma Solutions - Tennessee | 29 December 2020 |
| 30 capsule in 1 bottle | 71610-698-30 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 60 capsule in 1 bottle | 71610-698-53 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 90 capsule in 1 bottle | 71610-698-60 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 120 capsule in 1 bottle | 71610-698-70 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 180 capsule in 1 bottle | 71610-698-80 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 270 capsule in 1 bottle | 71610-698-92 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 360 capsule in 1 bottle | 71610-698-94 | Aphena Pharma Solutions - Tennessee | 4 April 2023 |
| 30 capsule in 1 bottle | 71610-720-30 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 60 capsule in 1 bottle | 71610-720-53 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 90 capsule in 1 bottle | 71610-720-60 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 120 capsule in 1 bottle | 71610-720-70 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 180 capsule in 1 bottle | 71610-720-80 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 270 capsule in 1 bottle | 71610-720-92 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
| 360 capsule in 1 bottle | 71610-720-94 | Aphena Pharma Solutions - Tennessee | 18 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 7 August 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Terazosin
Clinical summary
Terazosin is an alpha-adrenergic blocker indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH), among other approved uses. It is available as capsules and oral solution. MedsAcross supplies Terazosin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TerazosinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TEZRULY prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Terazosin 2 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.